RANDOMIZED STUDY OF ATOVAQUONE AND AZITHROMYCIN AS COMPARED TO TMP/SMZ

II/III期、随机、安慰剂对照、双臂、比较性艾滋病临床试验组（ACTG）研究。 在HIV感染者中建立AIDS诊断的两个重要标准是机会性感染的发展和复发或多重严重细菌感染的存在。 卡氏肺孢子虫肺炎（PCP）是儿童中最常见的机会性感染，占该年龄组所有艾滋病定义疾病的40%以上。 本研究的主要目的是确定阿奇霉素加阿托伐醌与甲氧苄啶/磺胺甲恶唑（TMP/SMX）预防严重细菌感染的可比性，并确定和比较微粉化阿托伐醌加阿奇霉素与TMP/SMX的长期安全性和耐受性。

Phase II/III, randomized, placebo-controlled, two-armed, comparison AIDS Clinical Trial Group (ACTG) study. Two important criteria for establishing an AIDS diagnosis in those with HIV infection are the development of an opportunistic infection and the presence of recurrent or multiple serious bacterial infections. Pneumocystis carinii pneumonia (PCP) is the most common opportunistic infection reported in children and has accounted for >40% of all AIDS defining illnesses in this age group. The primary aims of the study are to determine the comparability of azithromycin plus atovaquone to trimethoprim/sulfamethoxazole (TMP/SMX) in the prevention of serious bacterial infections and to determine and compare the long-term safety and tolerance of micronized atovaquone plus azithromycin versus TMP/SMX.